All In Biotech

Drug Trial Radar · NCT00772382

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

116

Actual

Start

Dec 2008

Primary completion

Aug 2010

Study completion Aug 2010

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Oct 15, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia. The secondary objective of this study is to assess the long-term efficacy of flexible doses of MCI-196.

Conditions

  • Chronic Kidney Disease
  • Dialysis
  • Hyperphosphatemia

Interventions

  • MCI-196Drug

    3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events (AE)Time frame: 52 weeks

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Orange, California

  • Site not named

    Tarzana, California

  • Site not named

    Orlando, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Gurnee, Illinois

  • Site not named

    Evansville, Indiana

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Northport, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Nashville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Burlington, Vermont

  • Site not named

    Chesapeake, Virginia

  • Site not named

    Kamloops, British Columbia, Canada

  • Site not named

    London, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.